Table 1 Clinical characteristics with PTEN status of cell lines examined
From: Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors
Cell line | Tumor histology | Grade | Recurrent/ metastatic | PTEN status | Mutation type | Specific mutations | Protein expression | References |
|---|---|---|---|---|---|---|---|---|
HEC-50 | Non-endometrioid | 3 | + | Wild type | – | – | + | 38–40 |
HEC-1B | Endometrioid | 3 | – | Wild type | – | – | + | 41 |
ISHIKAWA | Endometrioid | 2 | – | Mutated | Frameshift | Codon 289del A Codons 317–318 del ACTT | – | 42–44 |
AN3CA | Endometrioid | 3 | + | Mutated | Nonsense | Codon 130 del G | – | 43–46 |